About 62% in one year can surgery increase?

Pioneering robotic surgery shares Surgical intuitive (NASDAQ: ISRG) They have been shooting lately. A preliminary look at the sales results of the fourth quarter of 2024 suggests that his business is on the right track.

The recent performance and the perspective of Intuitive Surgical are excellent and the investors have been noticed. Well -established medical technology business shares increased by 62% during the 12 -month period, which ended on January 22, 2025.

Is it still a good time to buy intuitive surgical, or has it increased too much? Then I will examine some of the reasons why the shares have increased to see if it is not too late to buy some shares.

On January 15, Intuitive Surgical announced preliminary results of the fourth quarter of 2024. Its system of surgical robot Da Vinci represents a great investment for hospitals, but it is what it is ready to do. Hospitals around the world placed 493 Surgical Systems DA Vinci in the third quarter, 174 of which were new Da Vinci 5 systems.

The new DA Vinci 5 costs system between 2 and 2.5 million dollars. This is significantly more than the above iterations, but does not prevent hospitals from buying or leasing new systems.

The last surgical system of Intuitive Surgical could have a significant advantage with respect to the competition. Unlike StrykerEndoscopic tower teams, DA Vinci 5 integrate visualization and other functions in a single tower.

Intuitive surgical is not only to put many new generation surgical systems, but they sell piles of instruments that must be replaced by each procedure. Sales of instruments and accessories in the fourth quarter bouncing a higher year -on -year 23% up to $ 1.4 billion, or 58.5% of total income.

In addition to reporting preliminary results not audited in the fourth quarter of 2024, the intuitive surgical orientation issued by 2025. The company reported 18% of the Da Vinci procedure volume by 2024 that could be slightly decreased this year. The management provides that the volume of the procedure will increase from 13% to 16% by 2025.

As the only company that sells the instruments and accessories must use their Da Vinci 5 robots, Intuitive Surgical has a lot of prices. Sales of instruments and accessory sales usually exceed the volume of procedures at a few percentage points. That is, the company’s largest revenue flow will increase more than 13% by 2025.

In addition to an integrated tower, the new Da Vinci 5 system includes a strength feedback function that allows surgeons to intuit the thrust forces and runs that exercise the fabrics with their fingers instead of trusting on visual tracks.

Giant Medical Technology Johnson & Johnson (NYSE: JNJ) It is developing a new robotic surgical system, but it is a long way behind the market leader. J&J began registering patients in a clinical trial with their robotic surgical system Ottava last November.

With DA Vinci 5 that cement the main position of intuitive Surgical in the robot -assisted surgery market, the company’s actions are traded with a premium assessment. Investors have been paying a 77 -year -old sky Future time gains expectations for actions.

Intuitive Surgical has been negotiating with an induced nose assessment, as investors suppose he can retain his advantage after J&J launches his next generation system. It is a solid dissertation because the purchase of a new robot-assisted surgery system, as well as the training staff to use it, are great expenses that most hospitals would like to avoid.

Although there are good reasons to assume that intuitive surgical surgery has many years of growth ahead, individual investors should realize the risks involved in the purchase of a stock with such high assessment. If management problems advanced below Wall Street’s high expectations at any time over the next few years, the high assessment of the actions could fall. It is probably better to see this stock from a safe distance at the moment.

Have you ever wanted to lose the boat when buying stocks most successful? Then you want to hear that.

Rarely, our an analysts expert team emits a “Double Double -Double” Actions Recommendation for companies that think they are about to make appear. If you are concerned that you have already lost your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:

Nvidia: If you invested $ 1,000 when we doubled in 2009, would have 381,355 $!*
Apple: If you invested $ 1,000 when we doubled in 2008, would you have $ 42,390!*
Netflix: If you invested $ 1,000 when we doubled in 2004, would you have 514,479!*

Right now, we issue “double” alerts for three incredible companies, and maybe there is no other opportunity like this at any time.

Get more information »

*The Exchange Minister returns from January 21 2025

Cory Renauer It has no position in any of the stocks mentioned. The Motley Fool has positions and recommends surgical intuitive. The Motley Fool recommends Johnson & Johnson. The mold’s fool has a Outreach policy.

About 62% in one year can surgery increase? was originally published by Motley Fool

Source link